NEW YORK, Jan. 30, 2018 /PRNewswire/ -- SummaryRead the full report: https://www.reportlinker.com/p05298285
Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. There are a total of 223 products in development for this indication, by 158 companies and 19 academic institutions. Key companies active in this space include F. Hoffmann-La Roche, GlaxoSmithKline, AstraZeneca, MedImmune and Pfizer.Ureter or ureteral cancer affects the ureter, the tube that transports urine from the kidney to the urinary bladder. Symptoms and signs of the disease include bleeding from the urethra or blood in the urine, discharge from the urethra and enlarged lymph nodes in the groin area. There are a total of nine products in development for this indication, by six companies and two academic institutions.These products act on a wide range of targets, including a number of growth factor receptors and intracellular signal transducers. Within bladder cancer, the most commonly developed targets are Programmed Cell Death 1 Ligand 1 and Tubulin.The report "Bladder and Ureter Cancer Drug Development Pipeline Review, 2017" provides an overview of the bladder and ureter pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for these two indications, and features dormant and discontinued projects.Scope- Which companies are the most active within each pipeline?- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?- What are the most important R&D milestones and data publications to have happened in this disease area?Reasons to buy- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administrationRead the full report: https://www.reportlinker.com/p05298285
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement
View original content:http://www.prnewswire.com/news-releases/bladder-and-ureter-cancer-drug-development-pipeline-review-2017-300590467.html
SOURCE Reportlinker
